6533b852fe1ef96bd12aadc1
RESEARCH PRODUCT
Diffusion-weighted imaging in oncology: An update
Francesco GentiliCarmelo MessinaDamiano CarusoMarco CalandriPaola ScaliseAntonio BrunoRoberto GrassiAntonio BarileAlberto BrunoFederico BrunoIrene GrazziniRodolfo BignoneRaffaele NatellaPietro CoppolinoRiccardo De RobertisDomenico Albanosubject
OncologyCancer Researchmedicine.medical_specialtyReviewCancer imaginglcsh:RC254-282030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineMagnetic resonance imagingInternal medicinemedicineEffective diffusion coefficientcardiovascular diseasesapparent diffusion coefficient; cancer imaging; diffusion weighted imaging; magnetic resonance imaging; oncologic imagingmedicine.diagnostic_testbusiness.industryMagnetic resonance imagingDiffusion weighted imaginglcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensOncologic imagingClinical PracticeOncologyApparent diffusion coefficient030220 oncology & carcinogenesisCancer imagingbusinessDiffusion MRIdescription
To date, diffusion weighted imaging (DWI) is included in routine magnetic resonance imaging (MRI) protocols for several cancers. The real additive role of DWI lies in the “functional” information obtained by probing the free diffusivity of water molecules into intra and inter-cellular spaces that in tumors mainly depend on cellularity. Although DWI has not gained much space in some oncologic scenarios, this non-invasive tool is routinely used in clinical practice and still remains a hot research topic: it has been tested in almost all cancers to differentiate malignant from benign lesions, to distinguish different malignant histotypes or tumor grades, to predict and/or assess treatment responses, and to identify residual or recurrent tumors in follow-up examinations. In this review, we provide an up-to-date overview on the application of DWI in oncology.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-01-01 |